A complementary key role in the pathogenesis of NASH is played by impaired bile acid signaling, mediated by the FXR and fibroblast growth factor receptor 4 (FGFR4). This evidence concerns the gene FGFR4 and metabolic dysfunction-associated steatohepatitis.